The EMA position

Date 16 December 2018
Event ESMO Immuno-Oncology Congress 2018
Session Immuno-oncology endpoints for approval: The case of tumor agnostic approval for MSI-H cancers
Topics Bioethics, Legal, and Economic Issues
Presenter Francesco Pignatti
Authors F. Pignatti
  • European Medicines Agency (EMA), E14 4HB - London/GB